Restricted accessResearch articleFirst published online 2021-1
A stepwise approach for pharmacists: Cardiovascular risk reduction with novel antihyperglycemic agents in patients with type 2 diabetes and atherosclerotic cardiovascular disease
DasSEverettBBirtcherK, et al. 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.J Am Coll Cardiol2018;72(24):3200-23.
2.
PuymiratETaldirGAissaouiN, et al. Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovasc Interv2012;5(9):893-902.
3.
LawMWattHWaldN.The underlying risk of death after myocardial infarction in the absence of treatment. Arch Intern Med2002;162(21):2405-10.
4.
BataIGregorRWolfH, et al. Trends in five-year survival of patients discharged after acute myocardial infarction. Can J Cardiol2006;22(5):399-404.
5.
CurtisJSchreinerGWangY, et al. All-cause readmission and repeat revascularization after percutaneous coronary intervention in a cohort of medicare patients. J Am Coll Cardiol2009;54(10):903-7.
6.
MehtaSBaineyKCantorW, et al. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology focused update of the guidelinesfor the use of antipletelet therapy. Can J Cardiol2018;34(3):214-33.
7.
Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes2018;42(1):S1-S325.
8.
ZinmanBWannerCLachinJ, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med2015;373:2117-29.
9.
GersteinHColhounHDagenaisG, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet2019;394(10193):121-30.
10.
HernandezAGreenJJanmohamedS, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet2018;392(10157):1519-29.
11.
NealBPerkovicVMahaffeyK, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med2017;377:644-57.
12.
MarsoSDanielsGBrown-FrandsenK, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med2016;375:311-22.
13.
MarsoSBainSConsoliA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med2016;375(19):1834-44.
VardenyOVaduganathanM.Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. JACC Heart Fail2019;7(2):169-72.
18.
Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes2020;44(7):575-91.
19.
CosentinoFGrantPAboyansV, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the task force for diabetes, pre-diabets, and cardiovacular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J2019;41(2):255-323.
20.
WiviottSRazIBonacaM, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med2018;380(4):347-57.
RosenstockJFerranniniE.Euglycemic diabetic ketoacidosis: a predictable, detectable and preventable safety concern with SGLT2 inhibitors. Diabetes Care2015;38:1638-42.
26.
HandelsmanYHenryRBloomgardenZ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis. Endocrine Pract2016;22(6):753-62.
27.
RegierLLeBrasM.Diabetes treatment: glycemic management in T2DM. RxFiles Drug Comparison Charts. Saskatoon, SK: Saskatoon Health Region;2019. p 40-42. Available: rxfiles.ca/RxFiles/uploads/documents/members/cht-diabetes.pdf (accessed Nov. 5, 2019).
28.
WilliamsSAhmedH.1224-P: improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice. Diabetes2019;68(suppl 1).
